B. Riley Forecasts Lower Earnings for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI) – B. Riley decreased their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report released on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($0.80) for the quarter, down from their previous forecast of ($0.79). B. Riley has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics’ FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($1.38) EPS and FY2028 earnings at ($2.05) EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08.

A number of other analysts also recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group dropped their price target on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. HC Wainwright lifted their price target on Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. dropped their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Finally, Morgan Stanley started coverage on Denali Therapeutics in a research report on Friday. They set an “overweight” rating and a $33.00 price target for the company. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.27.

Denali Therapeutics Stock Up 2.6 %

Shares of NASDAQ DNLI opened at $16.69 on Friday. The company has a market cap of $2.40 billion, a P/E ratio of -6.05 and a beta of 1.43. The business has a 50-day simple moving average of $20.88 and a two-hundred day simple moving average of $24.35. Denali Therapeutics has a 52 week low of $14.01 and a 52 week high of $33.33.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 in the last ninety days. Company insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds have recently made changes to their positions in DNLI. FMR LLC increased its stake in shares of Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after buying an additional 1,451,770 shares during the period. Norges Bank purchased a new position in shares of Denali Therapeutics during the fourth quarter valued at approximately $21,717,000. Wellington Management Group LLP increased its stake in shares of Denali Therapeutics by 9.2% during the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after buying an additional 903,683 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after buying an additional 843,996 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.